New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2014
04:55 EDTAET, AET, AET, RNA, RNA, RNA, SHPG, SHPG, SHPG, ALXN, ALXN, ALXN, MSTX, MSTX, MSTX, NVS, NVS, NVS, SRPT, SRPT, SRPT, GENZ, GENZ, GENZ, FOLD, FOLD, FOLD, RXII, RXII, RXII, PFE, PFE, PFE, HUM, HUM, HUMTerrapinn to hold a conference
World Orphan Drug Congress is being held in Washington, D.C. on April 23-25.
News For HUM;PFE;RXII;FOLD;GENZ;SRPT;NVS;MSTX;ALXN;SHPG;RNA;AET From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
January 29, 2016
07:53 EDTNVSNovartis management to meet with JPMorgan
Subscribe for More Information
07:37 EDTNVSRadius Health should be bought aggressively at current prices, says Canaccord
Canaccord said they would be aggressive buyers of Radius Health (RDUS) especially at current share prices. The firm cited its partnership with Novartis (NVS), its drug pipeline, and expectations for an FDA filing of abaloparatide in the first quarter of 2016. Canaccord reiterated its Buy rating and $85 price target on Radius Health shares.
07:03 EDTAETAetna volatility elevated into Q4 and outlook
Aetna February weekly call option implied volatility is at 47, February and March is at 38; compared to its 52-week range of 18 to 44, suggesting large near term price movement into the expected release of Q4 results on February 1.
05:39 EDTPFEPfizer: LIS awards infliximab biosimilar tender to Inflectra, Reuters reports
Pfizer says that the Norwegian Drug Procurement Cooperation has awarded its product Inflectra an infliximab biosimilar tender, Reuters reports. Reference Link
January 28, 2016
17:01 EDTAETAetna enters four-year reinsurance arrangement with Vitality Re VII
Aetna announced it has entered into a four-year reinsurance arrangement with Vitality Re VII. The arrangement allows Aetna to reduce its required capital and provides $200M of collateralized excess of loss reinsurance coverage on a portion of Aetna's group commercial health insurance business.
12:09 EDTNVSRadius Health to hold a conference call
Subscribe for More Information
10:05 EDTSHPGHigh option volume stocks
Subscribe for More Information
09:38 EDTNVSNovartis downgraded to Neutral from Outperform at Exane BNP Paribas
Subscribe for More Information
January 27, 2016
16:33 EDTNVSRadius Health announces clinical collaboration with Novartis
Subscribe for More Information
12:19 EDTNVSPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
05:22 EDTNVSNovartis sees FY16 revenue, core operating income in line with FY15
Group net sales and core operating income in 2016 are expected to be broadly in line with the prior year, after absorbing the impact of generic competition. Generic competition impact on sales is expected to be as much as $3.2B compared to $2.2B in 2015.
05:20 EDTNVSNovartis reports Q4 core EPS $1.14, consensus $1.18
Subscribe for More Information
January 26, 2016
14:32 EDTNVSNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Novartis (NVS), consensus $1.18... Boeing (BA), consensus $1.26... United Technologies (UTX), consensus $1.52... Biogen (BIIB), consensus $4.08... EMC (EMC), consensus 65c... General Dynamics (GD), consensus $2.38... Anthem (ANTM), consensus $1.22... Illinois Tool Works (ITW), consensus $1.21... State Street (STT), consensus $1.18... Norfolk Southern (NSC), consensus $1.24... Progressive (PGR), consensus 47c... St. Jude Medical (STJ), consensus $1.01... Rockwell Automation (ROK), consensus $1.33... Textron (TXT), consensus 83c... Hess (HES), consensus ($1.47)... Cliffs Natural (CLF), consensus (26c).
11:34 EDTNVSJuno, Kite valuations at risk following study, TheStreet's Feuerstein says
Subscribe for More Information
10:06 EDTSRPTOptions with decreasing implied volatility
Options with decreasing implied volatility: SRPT GNC ALKS CALM NFLX CREE FFIV COH ISRG IBM
January 25, 2016
10:55 EDTNVSRegeneron slips after analyst says sell to avoid risk from Amgen patent suit
Shares of Regeneron Pharmaceuticals (REGN) fell in morning trading after an analyst at Chardan downgraded the stock to Sell, citing risk from a patent lawsuit in which the biopharmaceutical company is involved. CHARDAN SAYS SELL: Chardan Capital Markets analyst Gbola Amusa downgraded Regeneron to Sell from Neutral this morning, while reducing his price target on shares to $400 from $525. In a note to clients, Amusa said he believes that Regeneron is likely to face significant risks from the upcoming patent infringement case for Praluent. The suit could be a key driver of the company's share price performance in the near future, the analyst said. Regeneron, along with its partner Sanofi (SNY), launched Praluent in the U.S. last year, after the October 2014 filing of a patent infringement suit by Amgen (AMGN) relating to patents for "monoclonal antibodies that bind PCSK9," Amusa noted. The analyst believes that since Regeneron and Sanofi "likely" infringe Amgen's patents for Repatha, the Regeneron-Sanofi partnership could seek to settle the ahead of the trial by agreeing to pay 10%-20% or more of royalties to Amgen for U.S. Praluent sales. Amusa said that "such an outcome we estimate could transfer roughly $750M of operating income per year to Amgen." Further, Amusa said that catalysts surrounding the patent infringement trial are "likely to play out from late February to late March," and concedes that "both sides have good reasons to settle this case for a reasonable royalty." INCREASING COMPETITION: Amusa also noted that he sees increasing competitive risks in 2016 to Regeneron's Eylea from Novartis (NVS) and its partner Ophthotech (OPHT), which continue to progress Fovista into Phase III trials in wet AMD. WHAT'S NOTABLE: Roth Capital upgraded Regeneron to Buy from Neutral on January 19, based on valuation, as the firm said shares do not reflect the value of the company's upcoming catalysts. The firm also raised its price target to $555 from $543. The same day, Credit Suisse initiated Regeneron with a Neutral rating and $552 target. PRICE TARGET: Regeneron slipped 1.4% to $476.02 in morning trading.
10:22 EDTSRPTOptions with decreasing implied volatility
Options with decreasing implied volatility: SRPT SPWR NFLX CREE FFIV ISRG TIF MXIM QIHU IBM
09:08 EDTHUM, AETCalifornia seen asking for few remedies in health insurance mergers, CTFN says
Subscribe for More Information
08:23 EDTAET, HUMLeerink sees 'strong' buying opportunity in Managed Care space
Subscribe for More Information
07:02 EDTSHPGShire resubmits NDA for lifitegrast to FDA
Subscribe for More Information
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use